ArticleMolecular pharmaceutics2026
Assays for Measuring the Cell Permeability of Proteolysis-Targeting Chimeras (PROTACs): Performance, Correlations, Applicability and Recommendations.
Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most Proteolysis-Targeting Chimeras (PROTACs) are beyond-Rule-of-Five compounds, and optimizing their ability to cross cell membranes is a central topic in PROTAC therapeutic research. In this study, we systematically investigate the performance and assay correlations of PROTAC cell permeability assays and the chemical space in which these assays provide reliable results. Our work builds on a comprehensive data set of 3271 PROTACs spanning diverse chemical and target spaces, providing unprecedented coverage of PROTAC cell permeability data. These compounds were measured in up to three different types of assays: the NanoBRET E3 ligase target engagement assay, the Caco-2 assay, and a P-glycoprotein (P-gp) efflux liability assay. We find a strong correlation between readouts from the NanoBRET E3 ligase target engagement assay (availability shift) and those from the Caco-2 assay (apparent intrinsic permeability, basolateral-to-apical permeability, and efflux ratio), while P-gp liability derived from the P-gp assay cannot easily be translated to the Caco-2 efflux ratio. In the process, we also investigate the impact of physicochemical properties included in the Rule-of-Five on the applicability of the assays. Based on these findings, we derive guidelines and data-driven recommendations for the use of cell permeability assays in PROTAC optimization. While this study focuses on PROTACs, some of the observations may be relevant to other modalities with beyond-Rule-of-Five physicochemical properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.